Alzheimer's registry for people with memory problems
Part of Brain & nervous system, Mental health clinical trials.
This registry collects information from people with mild cognitive impairment or Alzheimer's disease who are starting a new medication. It helps researchers learn more about these conditions and their treatments over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild cognitive impairment or Alzheimer's disease (or a related dementia).
- You are at least 18 years old and can legally consent.
- You have a care partner (family or friend) who spends at least 10 hours a week with you and can come to clinic visits.
- You are about to start a new approved medication for Alzheimer's symptoms.
- You agree to provide your personal information (like name, birth date, and social security number) if you are in the U.S.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
This study creates a registry for people who are using newly approved Alzheimer's medications. It tracks how these treatments work over time and may help researchers learn more about diagnosing and treating Alzheimer's.
This is a research registry that helps doctors compare how different memory and Alzheimer’s risk groups change over time. It may help researchers learn which people are more likely to develop Alzheimer’s and how to better track early changes.
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.